LOS ANGELES, April 23 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC BB:
CBAI -
News), the umbilical cord blood stem cell preservation company (
http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that it has been named the 20th largest biotech/biomed company in the Los Angeles area by The Los Angeles Business Journal.
The prestigious business publication includes Cord Blood America in its annual ranking of top companies, in a list headed by Amgen, headquartered in Thousand Oaks. The business publication lists Cord Blood America with 15 employees and annual revenues topping $6 million.
Cord Blood is the second youngest public company on the list of twenty, having gone public in 2003. It was established to allow parents to store umbilical cord blood after birth. Stem cells from umbilical cords have already been used to successfully treat more than 70 medical conditions.
"Our growth has both been rapid and extraordinary," said Matthew L. Schissler, CEO and founder. "It is nice to see the Company recognized for its achievements and we are proud of what we have accomplished in such a short period of time."
About Cord Blood America
Cord Blood America (OTC BB: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (Pink Sheets: CBAI - News), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
